Submission Details
| 510(k) Number | K192291 FDA.gov |
| FDA Decision | Cleared SESE |
| Date Received | August 23, 2019 |
| Decision Date | August 20, 2020 |
| Days to Decision | 363 days |
| Submission Type | Traditional |
| Review Panel | General Hospital (HO) |
| Summary | Summary PDF |
K192291 is an FDA 510(k) clearance for the TidalPort-AP Implantable Apheresis Vascular Access Port, a Subcutaneous Implanted Apheresis Port (Class II — Special Controls, product code PTD), submitted by Norfolk Medical Products, Inc. (Skokie, US). The FDA issued a Cleared decision on August 20, 2020, 363 days after receiving the submission on August 23, 2019. This device falls under the General Hospital review panel. Regulated under 21 CFR 880.5965.
| 510(k) Number | K192291 FDA.gov |
| FDA Decision | Cleared SESE |
| Date Received | August 23, 2019 |
| Decision Date | August 20, 2020 |
| Days to Decision | 363 days |
| Submission Type | Traditional |
| Review Panel | General Hospital (HO) |
| Summary | Summary PDF |
| Product Code | PTD — Subcutaneous Implanted Apheresis Port |
| Device Class | Class II — Special Controls |
| CFR Regulation | 21 CFR 880.5965 |
| Definition | A Subcutaneous Implanted Apheresis Port Is A Prescription Device Intended For Patient Therapies Requiring Repeated Access To The Vascular System And Long-term Therapeutic Apheresis |